Evaluation of the Medical Device Vagitab - T as Adjuvant Therapy in Patients With Bacterial Vaginosis.

Inclusion Criteria: * Female patients aged from 18 to 65 years (inclusive). * Patients affected at enrolment by BV diagnosed according to Amsel criteria, candidate to start an antibiotic therapy with metronidazole. * Patient with a medical history of RBV (at least 2 episodes of BV in the last 12 months including the current episode). * Patients who are, in the opinion of the Investigator, able to understand the study, cooperate with the study procedures and attend all the study visits. * Patients who have given their written informed consent to participate in the study. Exclusion Criteria: * Patient with a medical history of HIV or any other immunodeficiency. * Patients working as sex workers. * Patients with known allergies or intolerance / hypersensitivity to the tested medical device and its components. * Patients with concomitant menstrual bleeding at baseline. * Time between the last day of last menses and treatment with metronidazole ≤ 3 days. * Pregnant, lactating, and lactating amenorrhoeic patients and patients of childbearing potential who are planning a pregnancy or unwilling to use appropriate methods of contraception during the study * Concomitant use of vaginal tampons. * Concomitant administration of etonogestrel/ethinyl estradiol vaginal rings or of intrauterine devices. * Concomitant use of oral or vaginal antibiotic therapy (apart from metronidazole) or any other vaginal therapies or treatment (such as douching, spermicide). * Concomitant use of oral or vaginal probiotics. * Patients with any other medical condition that, in the opinion of the Investigator, would compromise participation or be likely to lead to hospitalization during the study. * Concomitant or previous (in the previous 30 days) participation in any other interventional clinical trials